

Iago Rodríguez Lago

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7723522/publications.pdf>

Version: 2024-02-01

114
papers

905
citations

567281

15
h-index

552781

26
g-index

122
all docs

122
docs citations

122
times ranked

1516
citing authors

#	ARTICLE	IF	CITATIONS
1	Re-induction With Intravenous Ustekinumab in Patients With Crohn��s Disease and a Loss of Response to This Therapy. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 41-47.	1.9	13
2	SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project. <i>Gastroenterolog�� Y Hepatolog��</i> , 2022, 45, 737-741.	0.5	8
3	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 421.	2.4	8
4	Management and long-term outcomes of Crohn��s disease complicated with enterocutaneous fistula: ECUFIT study from GETECCU. <i>Journal of Crohn's and Colitis</i> , 2022, , .	1.3	0
5	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. <i>Frontiers in Medicine</i> , 2022, 9, 823900.	2.6	4
6	Young GI angle: Challenges and opportunities as a trainee editor: The United European Gastroenterology journal experience. <i>United European Gastroenterology Journal</i> , 2022, 10, 348-353.	3.8	5
7	Modifying the natural history of gastrointestinal diseases in Europe as a result of early diagnosis: From eosinophilic esophagitis to inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2022, 10, 612-613.	3.8	0
8	Preclinical Inflammatory Bowel Disease: Back to the Future. <i>Gastroenterology</i> , 2021, 160, 475-476.	1.3	3
9	How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. <i>Frontiers in Medicine</i> , 2021, 8, 640813.	2.6	17
10	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD��Prediction and Prevention of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1443-1454.	1.3	33
11	Risk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e99-e100.	1.9	0
12	Cytokine Storm in IBD: Balancing the Risks of IBD Medical Therapy. <i>Gastroenterology</i> , 2021, 160, 1878-1880.	1.3	1
13	P357 Long-term outcomes of biologic therapy in Crohn��s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S377-S378.	1.3	0
14	P210 Healthcare resources utilisation prior to the diagnosis of ulcerative colitis and Crohn��s disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S270-S270.	1.3	0
15	Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S553-S554.	1.3	1
16	DOP32 Long-term outcomes of enterocutaneous fistula complicating Crohn��s Disease: The ECUFIT study from GETECCU. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S070-S071.	1.3	0
17	P403 Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S410-S411.	1.3	2
18	P450 Vaccination strategies in Inflammatory Bowel Disease patients: perspective of physicians and patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S446-S446.	1.3	2

#	ARTICLE	IF	CITATIONS
19	DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. Journal of Crohn's and Colitis, 2021, 15, S078-S079.	1.3	0
20	P104 Inflammatory complications of the pouch, and therapeutic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU. Journal of Crohn's and Colitis, 2021, 15, S198-S199.	1.3	0
21	DOP37 Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey. Journal of Crohn's and Colitis, 2021, 15, S075-S076.	1.3	0
22	COVID��19 in gastroenterology: Where are we now? Current evidence on the impact of COVID��19 in gastroenterology. United European Gastroenterology Journal, 2021, 9, 750-765.	3.8	18
23	Increased use of healthcare resources during the preclinical period of inflammatory bowel disease. Digestive and Liver Disease, 2021, 53, 927-930.	0.9	3
24	Look at Both Sides of the Coin in Determining Risk of Complicated Crohn��s Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1503-1504.	4.4	0
25	Clinical features, therapeutic requirements and evolution of patients with Crohn��s disease and upper gastrointestinal involvement (CROHNEX study). Alimentary Pharmacology and Therapeutics, 2021, 54, 1041-1051.	3.7	6
26	The natural history of extraintestinal manifestations after surgery in inflammatory bowel disease: Never give up!. United European Gastroenterology Journal, 2021, 9, 748-749.	3.8	1
27	Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey. Gastroenterolog�� Y Hepatolog��, 2021, , .	0.5	2
28	Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterolog�� Y Hepatolog�� (English Edition), 2021, 44, 587-587.	0.1	1
29	Riesgo de infecci��n asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biol��gicas en enfermedad inflamatoria intestinal y artr��tis reumatoide. Estrategias de prevenci��n. Gastroenterolog�� Y Hepatolog��, 2021, 44, 587-598.	0.5	3
30	Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients�� behaviors. European Journal of Gastroenterology and Hepatology, 2021, 33, 501-507.	1.6	4
31	HMO-1��...Variation in IBD care and education across Europe results from a pan-European survey. , 2021, , .		0
32	Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry. Digestive and Liver Disease, 2021, , .	0.9	2
33	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflammatory Bowel Diseases, 2020, 26, 606-616.	1.9	29
34	Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 1112-1122.	2.4	20
35	The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn��s Disease. Journal of Crohn's and Colitis, 2020, 14, 557-566.	1.3	20
36	Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. Clinical and Translational Gastroenterology, 2020, 11, e00218.	2.5	8

#	ARTICLE	IF	CITATIONS
37	P200 Risk of progression of preclinical ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S238-S239.	1.3	0
38	P371 Self-medication with analgesics in ulcerative colitis: Results of a patient survey. Journal of Crohn's and Colitis, 2020, 14, S349-S350.	1.3	1
39	P544 Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry. Journal of Crohn's and Colitis, 2020, 14, S463-S464.	1.3	0
40	P550 Long-term effectiveness of anti-TNF agents in symptomatic stricturing Crohn's disease. Journal of Crohn's and Colitis, 2020, 14, S467-S468.	1.3	0
41	P571 Self-Medication with steroids in ulcerative colitis: Results of a patient survey. Journal of Crohn's and Colitis, 2020, 14, S480-S481.	1.3	1
42	N01 Factors related to self-medication with corticosteroids, aminosalicylates or analgesics and reasons given by patients with ulcerative colitis from Spain. Journal of Crohn's and Colitis, 2020, 14, S657-S657.	1.3	0
43	Tu1904 USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM ENEIDA REGISTRY. Gastroenterology, 2020, 158, S-1213.	1.3	0
44	COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020). Gastroenterology and Hepatology (English Edition), 2020, 43, 439-445.	0.1	0
45	Diagnosis and natural history of preclinical and early inflammatory bowel disease. Annals of Gastroenterology, 2020, 33, 443-452.	0.6	5
46	Usefulness of magnetic resonance enterography in the clinical decision-making process for patients with inflammatory bowel disease. Gastroenterology and Hepatology (English Edition), 2020, 43, 439-445.	0.1	0
47	Usefulness of magnetic resonance enterography in the clinical decision-making process for patients with inflammatory bowel disease. Gastroenterology and Hepatology, 2020, 43, 439-445.	0.5	2
48	Young GI Societies in Europe: 2019 update. United European Gastroenterology Journal, 2020, 8, 227-232.	3.8	10
49	Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. United European Gastroenterology Journal, 2020, 8, 1056-1066.	3.8	23
50	P159 Histopathological findings of preclinical inflammatory bowel disease. Journal of Crohn's and Colitis, 2020, 14, S218-S218.	1.3	0
51	Apoptotic colitis owing to dolutegravir. Gastroenterology and Hepatology (English Edition), 2020, 43, 638-639.	0.1	0
52	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. Gastroenterology and Hepatology (English Edition), 2020, 43, 439-445.	0.1	0
53	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 870-879.	3.7	12
54	Early microscopic findings in preclinical inflammatory bowel disease. Digestive and Liver Disease, 2020, 52, 1467-1472.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Recomendaciones del Grupo Espa��ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento. Gastroenterolog�� Y Hepatolog��, 2020, 43, 649-658.	0.5	7
56	Mo1860 REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY. Gastroenterology, 2020, 158, S-953.	1.3	1
57	P774 Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFELL registry of GETECCU. Journal of Crohn's and Colitis, 2020, 14, S614-S615.	1.3	0
58	Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain). Gastroenterology, 2020, 159, 781-783.	1.3	82
59	How to start a Young GI Section in your country: A cookbook. United European Gastroenterology Journal, 2020, 8, 355-358.	3.8	5
60	Colitis apopt��tica por dolutegravir. Gastroenterolog�� Y Hepatolog��, 2020, 43, 638-639.	0.5	1
61	Infecci��n gastrointestinal por Aeromonas: incidencia y su posible relaci��n con la enfermedad inflamatoria intestinal. Gastroenterolog�� Y Hepatolog��, 2020, 43, 614-619.	0.5	6
62	Pan-enteric capsule for bleeding high-risk patients. Can we limit endoscopies?. Revista Espanola De Enfermedades Digestivas, 2020, 113, 580-584.	0.3	5
63	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. Current Drug Metabolism, 2020, 21, 247-255.	1.2	4
64	Gastrointestinal infection with Aeromonas: incidence and relationship to inflammatory bowel disease. Gastroenterolog�� Y Hepatolog�� (English Edition), 2020, 43, 614-619.	0.1	4
65	P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry. Journal of Crohn's and Colitis, 2019, 13, S329-S330.	1.3	0
66	The relationship between inflammatory bowel disease and Parkinson��s disease: true or fiction?. Scandinavian Journal of Gastroenterology, 2019, 54, 886-889.	1.5	1
67	The combination of granulocyte��monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?. Journal of Clinical Apheresis, 2019, 34, 680-685.	1.3	14
68	Recomendaciones del Grupo Espa��ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 1: epidemiolog��, diagn��stico y pron��stico. Gastroenterolog�� Y Hepatolog��, 2019, 42, 568-578.	0.5	11
69	Su1865 ���� Real-World Short-Term Effectiveness of Ustekinumab in Crohn��s Disease: Results from the Eneida Registry. Gastroenterology, 2019, 156, S-641-S-642.	1.3	0
70	Short Disease Duration Does Not Always Indicate Early Crohn��s Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1646.	4.4	2
71	DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. Journal of Crohn's and Colitis, 2019, 13, S052-S053.	1.3	0
72	Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn��s disease patients: the Practicrohn study. Expert Review of Gastroenterology and Hepatology, 2019, 13, 807-813.	3.0	4

#	ARTICLE	IF	CITATIONS
73	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1492-1500.	1.3	37
74	Granulocyte��monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. Scandinavian Journal of Gastroenterology, 2019, 54, 459-464.	1.5	17
75	Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike��report of new cases and review of the literature. International Journal of Colorectal Disease, 2019, 34, 861-865.	2.2	17
76	Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. Gastroenterolog�� Y Hepatolog�� (English Edition), 2019, 42, 90-101.	0.1	2
77	UEG Young Talent Group: What do we do?. United European Gastroenterology Journal, 2019, 7, 166-168.	3.8	5
78	P223 Efficacy and safety of tacrolimus in Crohn��s disease: a nationwide, multi-centric study from GETECCU. Journal of Crohn's and Colitis, 2019, 13, S207-S208.	1.3	0
79	Immunosuppression for inflammatory bowel disease does not influence Epstein��Barr viral load in the short-term. Gastroenterolog�� Y Hepatolog�� (English Edition), 2019, 42, 542-547.	0.1	0
80	Recommendations of the Spanish Working Group on Crohn��s Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. Gastroenterolog�� Y Hepatolog�� (English Edition), 2019, 42, 568-578.	0.1	4
81	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987420.	3.2	5
82	Manejo de la colitis ulcerosa aguda grave en Espa��a: Resultados de una encuesta sobre pr��ctica cl��nica. Gastroenterolog�� Y Hepatolog��, 2019, 42, 90-101.	0.5	9
83	Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?. Turkish Journal of Gastroenterology, 2019, 29, 292-298.	1.1	5
84	UTILIDAD DE LA PANENDOSCOPIA POR C��PSULA EN EL ESTUDIO DE LA HDOO. ��PODEMOS DISMINUIR EL N��MERO DE ENDOSCOPIAS DIAGN��STICAS?. , 2019, , .		0
85	Immunosuppression for inflammatory bowel disease does not influence Epstein��Barr viral load in the short-term. Gastroenterolog�� Y Hepatolog��, 2019, 42, 542-547.	0.5	1
86	Long-Term Safety of In Utero Exposure to Anti-TNF�� Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. American Journal of Gastroenterology, 2018, 113, 396-403.	0.4	134
87	Validation of the ��United Registries for Clinical Assessment and Research�� [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 532-537.	1.3	8
88	Letter to Yokoyama et al. (Yokoyama Y. Cytokine. 2017 Dec 29; 103: 25��28). Cytokine, 2018, 104, 29.	3.2	0
89	Characteristics and Progression of Preclinical Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1459-1466.	4.4	27
90	Post-Operative Morbidity and Mortality of a Cohort of Steroid Refractory Acute Severe Ulcerative Colitis: Nationwide Multicenter Study of the GETECCU ENEIDA Registry. American Journal of Gastroenterology, 2018, 113, 1009-1016.	0.4	30

#	ARTICLE	IF	CITATIONS
91	Adalimumab treatment of anti-TNF-na�ve patients with ulcerative colitis: Deep remission and response factors. Digestive and Liver Disease, 2018, 50, 812-819.	0.9	11
92	Hyperamylasaemia and gastrointestinal bleeding as the first manifestation of jejunal ectopic pancreas. Gastroenterolog�a Y Hepatolog�a (English Edition), 2018, 41, 113-114.	0.1	0
93	Hyperamylasaemia and gastrointestinal bleeding as the first manifestation of jejunal ectopic pancreas. Gastroenterolog�a Y Hepatolog�a, 2018, 41, 113-114.	0.5	0
94	Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients�� point of view. Gastroenterolog�a Y Hepatolog�a, 2018, 41, 423-431.	0.5	10
95	Young GI angle: How to use e�resources when preparing for presentations and exams. United European Gastroenterology Journal, 2018, 6, 641-642.	3.8	0
96	Revisando el papel terap�utico de la budesonida en la enfermedad de Crohn. Gastroenterolog�a Y Hepatolog�a, 2018, 41, 458-471.	0.5	9
97	Reviewing the therapeutic role of budesonide in Crohn's disease. Gastroenterolog�a Y Hepatolog�a (English Edition), 2018, 41, 458-471.	0.1	5
98	Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients�� point of view. Gastroenterolog�a Y Hepatolog�a (English Edition), 2018, 41, 423-431.	0.1	1
99	Granulocyte��Monocyte Apheresis as an Adjuvant Therapy to Anti��Tumor Necrosis Factor Drugs for Ulcerative Colitis. Therapeutic Apheresis and Dialysis, 2017, 21, 26-30.	0.9	8
100	First case report of oesophageal actinomyces in a patient with active eosinophilic oesophagitis. Gastroenterolog�a Y Hepatolog�a (English Edition), 2017, 40, 404-406.	0.1	0
101	Primer caso cl�nico de actinomicosis esof�gica en un paciente con esofagitis eosinof�lica activa. Gastroenterolog�a Y Hepatolog�a, 2017, 40, 404-406.	0.5	2
102	Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?. BMC Cancer, 2017, 17, 577.	2.6	39
103	Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease. Revista Espanola De Enfermedades Digestivas, 2016, 108, 550-7.	0.3	2
104	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15006.	4.1	15
105	Endoscopic closure of tracheoesophageal fistula with submucosal dissection and a biosynthetic mesh. Endoscopy, 2015, 47, E312-E313.	1.8	2
106	Pseudoachalasia secondary to infiltration of the pillars of the diaphragm by an urotelial tumor: Diagnostic approach with endoscopic ultrasound. Revista Espanola De Enfermedades Digestivas, 2015, 107, 121-2.	0.3	1
107	Esophageal Chicken Pox in a Patient on Immunosuppressive Therapy. Clinical Gastroenterology and Hepatology, 2013, 11, A33.	4.4	2
108	Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. World Journal of Gastroenterology, 2013, 19, 2935-2940.	3.3	22

#	ARTICLE	IF	CITATIONS
109	Small-bowel migration: a possible complication of adjustable intragastric balloons. Endoscopy, 2012, 44, E224-E224.	1.8	6
110	Gastrointestinal Bleeding Caused by Primary Small Bowel Lymphoma in a Patient Who Received a Renal Transplant. Clinical Gastroenterology and Hepatology, 2012, 10, e2.	4.4	10
111	Herpetic esophagitis: a case report on an immunocompetent adolescent. Revista Espanola De Enfermedades Digestivas, 2012, 104, 214-217.	0.3	12
112	Successful endoscopic mesh removal after laparoscopic Nissen fundoplication. Revista Espanola De Enfermedades Digestivas, 2012, 104, 605-606.	0.3	0
113	Colocolonic intussusception secondary to high grade colonic leiomyosarcoma. Revista Espanola De Enfermedades Digestivas, 2011, 103, 602-603.	0.3	5
114	Colocolonic intussusception secondary to high grade colonic leiomyosarcoma. Revista Espanola De Enfermedades Digestivas, 2011, 103, 601-3.	0.3	0